Last reviewed · How we verify
Spironolactone 100mg
At a glance
| Generic name | Spironolactone 100mg |
|---|---|
| Also known as | Aldactone |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke (PHASE2)
- Spironolactone for Pulmonary Arterial Hypertension (PHASE2)
- Spironolactone Improved Children With Gene Mutations Related to NCOR (PHASE2, PHASE3)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- HEART: Pilot Randomized Controlled Trial (PHASE1, PHASE2)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone 100mg CI brief — competitive landscape report
- Spironolactone 100mg updates RSS · CI watch RSS
- Columbia University portfolio CI